KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Accumulated Expenses (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Accumulated Expenses data on record, last reported at $270.1 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 50.53% year-over-year to $270.1 million; the TTM value through Dec 2025 reached $270.1 million, up 50.53%, while the annual FY2025 figure was $270.1 million, 50.53% up from the prior year.
  • Accumulated Expenses reached $270.1 million in Q4 2025 per CRL's latest filing, up from $228.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $270.1 million in Q4 2025 and bottomed at $165.2 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $214.6 million, with a median of $220.2 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 74.43% in 2021, then dropped 19.95% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $228.8 million in 2021, then decreased by 3.95% to $219.8 million in 2022, then dropped by 2.94% to $213.3 million in 2023, then dropped by 15.88% to $179.4 million in 2024, then surged by 50.53% to $270.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $270.1 million in Q4 2025, $228.9 million in Q3 2025, and $227.5 million in Q2 2025.